Partnerships, funders, and financial interests
We receive funding from a range of commercial organisations for areas of our work where we have shared interests. We ensure these partnerships are open and transparent at all times.
Trusts, Foundations & grant givers
In our last full financial year trusts, foundations and grants were received from: A M Pilkington Charitable Trust, The Beale Trust, D M Charitable Trust, Edgar Lee Foundation, Emily’s Dash Foundation, G F Eyre Charitable Trust, G M Morrison Charitable Trust, Gilbert and Eileen Edgar Foundation, Hobson Charity, John M Archer Charitable Trust, Merkle Foundation, Mrs Vera Leigh’s Charity, the National Lottery Community Fund, Tableau Foundation, Vera Outhwaite Charitable Trust, Wyndham Charitable Trust and UNICEF.
Law firms who support families affected by meningitis
Law firms is a sector represented amongst our corporate supporters. We are committed to offering the best advice and support possible to our beneficiaries, and this network of independently accredited experts help us to provide up-to-date and accurate information, and signpost to high quality specialist advice where appropriate.
Other corporate support
Companies that have supported us through generous gifts in kind, corporate donations, payroll giving, Charity of the Year relationships, and by supporting and enabling their teams to fundraise for us in our last full financial year are: Bord Na Mona, Bristows LLP, Computer World, Deloitte, Hawk Incentives, HB Projects, The Information Lab, Media Lab, MFS Assets Management, and Owens.
Pharmaceutical companies working to prevent meningitis through vaccination
In the last financial year, we received support from Pfizer, GSK, Sanofi and Serum Institute of India, as pharmaceutical companies who share our aim of preventing people from getting meningitis. Our policy is to receive no more than 25% of our total income from pharmaceutical companies. These sponsors do not influence the work we provide but fund specific projects, which are transparently listed in our policy on Funding from pharmaceutical companies (below).
Full disclosure of our income is available for anyone to read in our annual accounts.